UNSPSC 51123402: Dazolicine

This classification denotes an antiarrhythmic agent with the molecular formula C17H24ClN3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 92KE01WH2P, chemically known as 8-chloro-3,4,5,6-tetrahydro-6-((1-isopropyl-2-imidazolin-2-yl)methyl)-2h-1,6-benzothiazocine but more generally known as dazolicine, which bears US NIH Compound Identifier 68810. European Medicines Agency schedules Dazolicine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06922MIG.

UNSPSC 51123402 Dazolicine, a Commodity code, covers the procurement of specific pharmaceutical products for emergency medical services, public health programs, and institutional healthcare systems operated or funded by state and local government. State and local agencies are sourcing advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products through direct manufacturer contracts, cooperative purchasing agreements, and competitive sealed-bid procurements. The issuing bodies span city fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of participating municipalities and state agencies. Scope includes supply of pre-filled syringes, vials, and injections with firm pricing, strict expiration-date warranties (typically nine months to one year minimum shelf life), rapid delivery windows (often ten calendar days or less), and compliance with FDA requirements, Good Manufacturing Practices, and OSHA Safety Data Sheet standards.

Recent activity concentrates in Florida and Minnesota, with Texas conducting exploratory procurement for direct-to-manufacturer prescription initiatives. Representative solicitations include the City of Tampa Fire Rescue's sealed-bid procurement (No. 26P00188, due April 8, 2026) for 4,530 units of advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem with an estimated contract value of $40,000 and one-year initial term plus renewal options; the Minnesota Multistate Cooperative Purchasing Alliance's RFP (No. S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson) with July 1, 2026 implementation and weighted evaluation favoring price competitiveness at 75 percent; and the Texas Health and Human Services Commission's Request for Information (No. HHS0017013, deadline April 3, 2026) exploring direct-to-manufacturer prescription programs for state agency and self-insured employer plans. Cooperative purchasing vehicles and multistate alliances appear active, and SLBE set-asides with bid discounts (Tampa example: 5 percent SLBE discount not to exceed $10,000) are present in municipal solicitations.